JPWO2021231657A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021231657A5 JPWO2021231657A5 JP2022569027A JP2022569027A JPWO2021231657A5 JP WO2021231657 A5 JPWO2021231657 A5 JP WO2021231657A5 JP 2022569027 A JP2022569027 A JP 2022569027A JP 2022569027 A JP2022569027 A JP 2022569027A JP WO2021231657 A5 JPWO2021231657 A5 JP WO2021231657A5
- Authority
- JP
- Japan
- Prior art keywords
- features
- composition
- cells
- subject
- cas3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 376
- 210000004027 cell Anatomy 0.000 claims description 239
- 230000001225 therapeutic effect Effects 0.000 claims description 224
- 230000004044 response Effects 0.000 claims description 169
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 163
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 148
- 238000000034 method Methods 0.000 claims description 112
- 238000011282 treatment Methods 0.000 claims description 102
- 201000010099 disease Diseases 0.000 claims description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 68
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 40
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 40
- 102100027207 CD27 antigen Human genes 0.000 claims description 36
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 36
- 238000011285 therapeutic regimen Methods 0.000 claims description 35
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 33
- 230000004083 survival effect Effects 0.000 claims description 31
- 230000008791 toxic response Effects 0.000 claims description 31
- 108700012920 TNF Proteins 0.000 claims description 27
- 238000007781 pre-processing Methods 0.000 claims description 25
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 24
- 101150106931 IFNG gene Proteins 0.000 claims description 24
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 24
- 238000007637 random forest analysis Methods 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 238000002512 chemotherapy Methods 0.000 claims description 15
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 15
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 208000037821 progressive disease Diseases 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 8
- 102100033461 Interleukin-17A Human genes 0.000 claims description 8
- 206010029350 Neurotoxicity Diseases 0.000 claims description 8
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 8
- 230000007135 neurotoxicity Effects 0.000 claims description 8
- 231100000228 neurotoxicity Toxicity 0.000 claims description 8
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims description 7
- 102100037850 Interferon gamma Human genes 0.000 claims description 7
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000012549 training Methods 0.000 claims description 6
- 230000000779 depleting effect Effects 0.000 claims description 5
- 101100457310 Arabidopsis thaliana MIP1A gene Proteins 0.000 claims description 4
- 101100457311 Arabidopsis thaliana MIP1B gene Proteins 0.000 claims description 4
- 102100031092 C-C motif chemokine 3 Human genes 0.000 claims description 4
- 102100031102 C-C motif chemokine 4 Human genes 0.000 claims description 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 4
- 102100032752 C-reactive protein Human genes 0.000 claims description 4
- 108700012434 CCL3 Proteins 0.000 claims description 4
- 101150116911 CCL3 gene Proteins 0.000 claims description 4
- 101150047126 CCL4 gene Proteins 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 4
- 102000003816 Interleukin-13 Human genes 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 238000002617 apheresis Methods 0.000 claims description 4
- 210000003651 basophil Anatomy 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000004820 blood count Methods 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 210000003979 eosinophil Anatomy 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 230000035899 viability Effects 0.000 claims description 4
- 206010057248 Cell death Diseases 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 231100000956 nontoxicity Toxicity 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 2
- 108010082126 Alanine transaminase Proteins 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 238000008789 Direct Bilirubin Methods 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 238000011319 anticancer therapy Methods 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000005534 hematocrit Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000009092 lines of therapy Methods 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- -1 red blood cell count Proteins 0.000 claims description 2
- 208000037922 refractory disease Diseases 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 238000009121 systemic therapy Methods 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 229940116269 uric acid Drugs 0.000 claims description 2
- 238000010801 machine learning Methods 0.000 claims 26
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 101100005249 Escherichia coli (strain K12) ygcB gene Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 101150055191 cas3 gene Proteins 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024494P | 2020-05-13 | 2020-05-13 | |
| US63/024,494 | 2020-05-13 | ||
| US202063037592P | 2020-06-10 | 2020-06-10 | |
| US63/037,592 | 2020-06-10 | ||
| PCT/US2021/032104 WO2021231657A1 (en) | 2020-05-13 | 2021-05-12 | Methods of identifying features associated with clinical response and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528215A JP2023528215A (ja) | 2023-07-04 |
| JPWO2021231657A5 true JPWO2021231657A5 (zh) | 2024-05-20 |
Family
ID=76270083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022569027A Pending JP2023528215A (ja) | 2020-05-13 | 2021-05-12 | 臨床応答に関連する特徴量の特定方法およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230178239A1 (zh) |
| EP (1) | EP4150640A1 (zh) |
| JP (1) | JP2023528215A (zh) |
| KR (1) | KR20230024283A (zh) |
| CN (1) | CN115803824A (zh) |
| WO (1) | WO2021231657A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11423000B2 (en) * | 2020-04-02 | 2022-08-23 | Sap Se | Data transfer and management system for in-memory database |
| WO2023178104A2 (en) * | 2022-03-14 | 2023-09-21 | Notch Therapeutics (Canada) Inc. | Apparatus and methods for a knowledge processing system that applies a reasoning technique for cell-based analysis to predict a clinical outcome |
| US20240112750A1 (en) * | 2022-10-04 | 2024-04-04 | BioCurie Inc. | Data-driven process development and manufacturing of biopharmaceuticals |
| WO2024086238A1 (en) * | 2022-10-19 | 2024-04-25 | Net/Bio, Inc. | Methods and systems for assessing dose-dependent response of a subject to an intervention |
| CN117743957B (zh) * | 2024-02-06 | 2024-05-07 | 北京大学第三医院（北京大学第三临床医学院） | 一种基于机器学习的Th2A细胞的数据分选方法及相关设备 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (zh) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ES2067018T3 (es) | 1988-12-28 | 1995-03-16 | Stefan Miltenyi | Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| AU6467796A (en) | 1996-04-24 | 1997-05-15 | Claude Fell | Cell separation system for biological fluids like blood |
| ATE466948T1 (de) | 1997-03-11 | 2010-05-15 | Univ Minnesota | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle |
| JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖ｔ細胞レセプタータンパク質 |
| CA2309000A1 (en) | 1997-11-13 | 1999-05-27 | Regents Of The University Of Minnesota | Tc1-based transposon vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| NZ507887A (en) | 1998-05-19 | 2002-12-20 | Avidex Ltd | Soluble T cell receptor |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| WO2000038762A1 (en) | 1998-12-24 | 2000-07-06 | Biosafe S.A. | Blood separation system particularly for concentrating hematopoietic stem cells |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP1287357A2 (en) | 2000-06-02 | 2003-03-05 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| CA2425862C (en) | 2000-11-07 | 2013-01-22 | City Of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7362449B2 (en) | 2003-05-16 | 2008-04-22 | Universite Libre De Bruxelles | Digital holographic microscope for 3D imaging and process using it |
| SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
| CN112480257A (zh) | 2005-03-23 | 2021-03-12 | 根马布股份公司 | 用于治疗多发性骨髓瘤的cd38抗体 |
| MX2007011218A (es) | 2005-03-23 | 2007-10-17 | Biosafe Sa | Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa. |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP3357338A1 (en) | 2007-03-30 | 2018-08-08 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| NO2227271T3 (zh) | 2007-12-07 | 2018-06-23 | ||
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| DK2222861T3 (en) | 2007-12-11 | 2018-02-05 | Univ North Carolina Chapel Hill | POLYPURIN-TRACT MODIFIED RETROVIRAL VECTORS |
| JP5990365B2 (ja) | 2007-12-26 | 2016-09-14 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする剤及びその使用 |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US8603477B2 (en) | 2008-10-31 | 2013-12-10 | Abbvie Biotherapeutics Inc. | Use of anti-CS1 antibodies for treatment of rare lymphomas |
| ES2593583T3 (es) | 2009-03-10 | 2016-12-09 | Biogen Ma Inc. | Anticuerpos anti-BCMA |
| US8466260B2 (en) | 2009-04-01 | 2013-06-18 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| CA2779526C (en) | 2009-11-03 | 2022-12-06 | City Of Hope | Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection |
| GB2497912B (en) | 2010-10-08 | 2014-06-04 | Harvard College | High-throughput single cell barcoding |
| WO2012048340A2 (en) | 2010-10-08 | 2012-04-12 | President And Fellows Of Harvard College | High-throughput immune sequencing |
| BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AU2012230780B2 (en) | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| CA2842377C (en) | 2011-07-19 | 2019-08-27 | Ovizio Imaging Systems N.V. | A method and system for detecting and/or classifying cancerous cells in a cell sample |
| KR102134932B1 (ko) | 2011-11-11 | 2020-07-17 | 프레드 헛친슨 켄서 리서치 센터 | 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법 |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| CN104395462B (zh) | 2012-05-03 | 2017-09-26 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| RS61345B1 (sr) | 2012-08-20 | 2021-02-26 | Hutchinson Fred Cancer Res | Postupak i kompozicije za ćelijsku imunoterapiju |
| EP2898310B1 (en) | 2012-09-20 | 2019-05-01 | Ovizio Imaging Systems NV/SA | Digital holographic microscope with fluid systems |
| ES2743738T3 (es) | 2012-10-02 | 2020-02-20 | Memorial Sloan Kettering Cancer Center | Composiciones y métodos para inmunoterapia |
| WO2014144495A1 (en) | 2013-03-15 | 2014-09-18 | Abvitro, Inc. | Single cell bar-coding for antibody discovery |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
| CA2933707A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| MA51794A (fr) | 2014-04-23 | 2020-05-06 | Juno Therapeutics Inc | Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| JP6672310B2 (ja) | 2014-09-15 | 2020-03-25 | アブビトロ， エルエルシー | ハイスループットヌクレオチドライブラリーシークエンシング |
| TWI735418B (zh) | 2014-11-05 | 2021-08-11 | 美商奇諾治療有限公司 | 用於轉導作用及細胞處理之方法 |
| CN113429482A (zh) | 2014-12-05 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的抗体和使用方法 |
| AU2015357526B2 (en) | 2014-12-05 | 2022-03-17 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof |
| WO2016090312A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| EP3872094A3 (en) | 2014-12-05 | 2021-12-08 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| CA2983937A1 (en) | 2015-04-27 | 2016-11-03 | Abvitro Llc | Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens |
| CN113774495A (zh) | 2015-09-25 | 2021-12-10 | 阿布维特罗有限责任公司 | 用于对天然配对t细胞受体序列进行t细胞受体靶向鉴别的高通量方法 |
| CN109328074A (zh) | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| JP2019532997A (ja) | 2016-11-03 | 2019-11-14 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｂｔｋ阻害剤との併用療法 |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| EP3548083A1 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
| US20200191774A1 (en) | 2017-02-27 | 2020-06-18 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| FI3618842T3 (fi) | 2017-05-01 | 2023-12-15 | Juno Therapeutics Inc | Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä |
| CN111225675B (zh) | 2017-06-02 | 2024-05-03 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法治疗的制品和方法 |
| US20200239910A1 (en) | 2017-08-09 | 2020-07-30 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| AU2018360800A1 (en) | 2017-11-01 | 2020-05-14 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) |
| BR112020008340A2 (pt) | 2017-11-01 | 2020-11-17 | Juno Therapeutics Inc | processo para gerar composições terapêuticas de células modificadas |
| AU2018367925A1 (en) * | 2017-11-17 | 2020-07-02 | Gmdx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
| WO2019113559A2 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| EP3746117A1 (en) | 2018-01-31 | 2020-12-09 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| EP3773658A4 (en) * | 2018-04-06 | 2022-04-27 | Dana-Farber Cancer Institute, Inc. | KIR3DL3 USEFUL AS HHLA2 RECEPTOR, ANTI-HHLA2 ANTIBODIES AND THEIR USES |
| MX2020011527A (es) | 2018-05-03 | 2021-02-26 | Juno Therapeutics Inc | Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa. |
| WO2020056346A1 (en) * | 2018-09-13 | 2020-03-19 | The Trustees Of The University Of Pennsylvania | Interferon pathway genes regulate and predict efficacy of immunotherapy |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| KR20210117260A (ko) | 2018-11-30 | 2021-09-28 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료방법 |
-
2021
- 2021-05-12 US US17/924,652 patent/US20230178239A1/en active Pending
- 2021-05-12 KR KR1020227043587A patent/KR20230024283A/ko unknown
- 2021-05-12 WO PCT/US2021/032104 patent/WO2021231657A1/en unknown
- 2021-05-12 JP JP2022569027A patent/JP2023528215A/ja active Pending
- 2021-05-12 CN CN202180048161.6A patent/CN115803824A/zh active Pending
- 2021-05-12 EP EP21730040.9A patent/EP4150640A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11705220B2 (en) | Systems and methods for identifying cancer treatments from normalized biomarker scores | |
| Parkman et al. | Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation | |
| Staels et al. | Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome | |
| McCurdy et al. | Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning | |
| Roussel et al. | Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome | |
| Caimi et al. | Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma | |
| Sloand et al. | Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy | |
| Burrows et al. | Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development | |
| Tricot et al. | Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization | |
| Törlén et al. | Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome | |
| Petersen et al. | A comparison of T-, B-and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors | |
| Toor et al. | Dynamical system modeling of immune reconstitution after allogeneic stem cell transplantation identifies patients at risk for adverse outcomes | |
| Solders et al. | Mucosal-associated invariant T cells display a poor reconstitution and altered phenotype after allogeneic hematopoietic stem cell transplantation | |
| e Sousa et al. | Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease | |
| Matos et al. | Maturation and phenotypic heterogeneity of human CD4+ regulatory T cells from birth to adulthood and after allogeneic stem cell transplantation | |
| Del Bufalo et al. | Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL | |
| Cardozo-Ojeda et al. | Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation | |
| Gyurkocza et al. | Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? | |
| JPWO2021231657A5 (zh) | ||
| Panagiota et al. | Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients | |
| Stieglitz et al. | Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group | |
| Frazer et al. | Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia | |
| Mehta et al. | Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial | |
| Streck et al. | Demographic and clinical donor characteristics as predictors of total nucleated cell concentrations in harvested marrow products | |
| Bobba et al. | Mycobacterium tuberculosis infection drives differential responses in the bone marrow hematopoietic stem and progenitor cells |